Eli Lilly and Company: Comprehensive Deep Dive Research Report

Prepared for: Ada Cockpit
Date: March 2026
Classification: Investor-Grade Analysis

Executive Summary

Company Overview

Eli Lilly and Company (NYSE: LLY) is an American multinational pharmaceutical corporation headquartered at Lilly Corporate Center, Indianapolis, Indiana. Founded on May 10, 1876, by Colonel Eli Lilly, the company has evolved from a small pharmaceutical operation into one of the world's leading healthcare innovators. As of March 2026, Eli Lilly employs approximately **35,000+ professionals globally** and operates in approximately 125 countries worldwide.

2025 REVENUE

$65.2B

+45% YoY

MARKET CAP (MAR 2026)

$897-953B

Top 13-14 globally

2026 GUIDANCE

$80-83B

+25% projected

TIRZEPATIDE FRANCHISE

$36.5B

56% of total revenue

2024 REVENUE

$45.0B

+32% YoY

US MARKET SHARE (INCRETINS)

60%

Leading position

Key Financial Metrics (Latest Fiscal Year)

Metric	2024 Full Year	2025 Full Year	Growth
Total Revenue	$45.0 billion	$65.2 billion	+45%
Market Capitalization	$704.3 billion	$966.2 billion	+37%
Q4 Revenue	$13.53 billion	$19.3 billion	+43%

Note: EBITDA and EBITDA margin figures are not explicitly disclosed in available earnings releases. Full-year 2024 net income for Q4 was $4.41 billion (EPS $4.88 reported, $5.32 non-GAAP). Q3 2025 reported net income was $5.58 billion (EPS $6.21 reported, $7.02 non-GAAP).

2025 Revenue Mix by Segment (Total: $65.2B)



Tirzepatide (Mounjaro + Zepbound) | Oncology (Verzenio, Kisunla, Jaypirca) | Immunology (Taltz, Omvoh, Ebglyss) | Jardiance | Legacy/Other



Strategic Position and Growth Trajectory

Eli Lilly has transformed from managing patent cliffs on legacy diabetes drugs to achieving unprecedented growth driven by incretin-based therapies. The company's tirzepatide franchise (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea) generated combined revenue of **$36.5 billion in 2025**, representing approximately 56% of total company revenue and nearly 100% year-over-year growth. This positions Lilly as the clear leader in the global GLP-1 receptor agonist market, surpassing Novo Nordisk in market share.

The company's oncology portfolio, led by Verzenio (abemaciclib) with $5.7 billion in 2025 sales, and immunology franchise anchored by Taltz ($3.2 billion in 2024) and Jardiance ($3.3 billion in 2024), provide diversification beyond metabolic diseases. Lilly's neuroscience portfolio includes Kisunla (donanemab), the second FDA-approved anti-amyloid therapy for early Alzheimer's disease, approved in 2024 with label updates in 2025.

Eli Lilly's market capitalization reached approximately **$897-953 billion as of March 2026**, making it one of the world's 13-14 most valuable companies and positioning it to become the world's

largest pharmaceutical company by revenue by 2030, with analyst projections of **$113 billion in sales**.

Medium-Term Targets and Strategic Priorities

Lilly has issued **2026 revenue guidance of $80-83 billion**, representing a 25% increase from 2025's $65.2 billion. For 2027, analysts project revenue reaching approximately **$87-94 billion** under base-case scenarios.

Strategic priorities include:

1. **Oral obesity drug dominance:** The anticipated **April 2026 FDA decision on orforglipron**, Lilly's once-daily oral GLP-1 receptor agonist, represents the most critical near-term catalyst. Analysts estimate orforglipron could achieve **$100 billion in peak sales** by the 2030s if it maintains Phase III efficacy profiles.
2. **Market share expansion:** Lilly currently controls nearly **60% of U.S. incretin prescriptions** and has overtaken Novo Nordisk as the weight-loss market leader.
3. **Manufacturing infrastructure:** The company has committed over **$50 billion to U.S. manufacturing expansion** since 2020, including a $6.5 billion Texas facility for orforglipron production, a $4.5 billion Indiana foundry, and a $1.2 billion Puerto Rico expansion focused on small-molecule GLP-1 manufacturing.
4. **Pipeline diversification:** Over 75% of new medicines in development target areas outside incretins, including oncology, immunology, neuroscience, and cardiovascular disease.

Forward-Looking Disclaimer: This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section, including but not limited to: competitive pressures from biosimilars and novel therapies, patent expirations, pricing and reimbursement pressures from government programs including Medicare drug price negotiations under the Inflation Reduction Act, regulatory approval uncertainties, manufacturing and supply chain challenges, foreign exchange volatility, and macroeconomic conditions. Past performance does not guarantee future results. Investors should conduct independent due diligence and consult with qualified advisors before making investment decisions.

Drug Portfolio Overview

Cardiometabolic Health / Endocrinology Portfolio

Product	Indication(s)	2024 Revenue	2025 Revenue	Growth	Patent/Exclusivity Status
Mounjaro (tirzepatide)	Type 2 diabetes	~$11.5B (est.)	$22.97B	+99%	NCE expires 2027; formulation to 2037
Zepbound (tirzepatide)	Obesity; OSA with obesity	~$4.9B (est.)	$13.54B	+175%	NCE expires 2027; formulation to 2037
Jardiance (empagliflozin)	T2DM; heart failure; CKD	$3.3B	Not disclosed	+22% (2024 YoY)	US compound patent May 2028
Trulicity (dulaglutide)	Type 2 diabetes	$5-6B (est.)	Declining	-25% in Q4 2024	Patent expiry 2027

Oncology, Immunology, and Neuroscience Portfolio

Product	Indication(s)	2024 Revenue	2025 Revenue	Peak Sales Potential
Verzenio (abemaciclib)	HR+/HER2- breast cancer (early, metastatic)	$5.3B	$5.7B	$8.1B by 2030
Taltz (ixekizumab)	Plaque psoriasis; PsA; AxSpA	$3.2B	Not disclosed	$4-5B (est.)
Kisunla (donanemab)	Early Alzheimer's disease	Minimal (launched 2024)	$0.4B (Q4 annualized)	$5-10B (long-term est.)
Jaypirca (pirtobrutinib)	Mantle cell lymphoma	Minimal	Growing (+30% Q4)	$1-2B (est.)
Omvoh (mirikizumab)	Ulcerative colitis; Crohn's disease	Minimal	Growing	$2-3B (est.)
Ebglyss (lebrikizumab)	Moderate-to-severe atopic dermatitis	Minimal	Growing	$1-2B (est.)

Top 5 CEO Focus Drugs

Based on earnings calls, investor presentations, and press releases from 2024-2026, CEO David Ricks and Lilly leadership have consistently emphasized the following drugs as strategic priorities:

Rank	Drug	Status	Key Catalyst	Peak Sales Potential
1	**Orforglipron** (oral GLP-1)	Phase III	April 2026 FDA decision (priority review)	$100B by 2030s (combined with oral GLP-1 portfolio)
2	**Tirzepatide** (Mounjaro/Zepbound)	Marketed	Manufacturing expansion; OSA indication	Mounjaro $36B, Zepbound $25.5B by 2030
3	**Retatrutide** (triple agonist)	Phase III (TRIUMPH)	Phase III readouts 2026-2027	$10-20B+ (if efficacy matches Phase II: 24% weight loss)
4	**Verzenio** (abemaciclib)	Marketed	Early breast cancer expansion (monarchE OS data)	$8.1B by 2030
5	**Kisunla** (donanemab)	Marketed (2024 approval)	Medicare coverage expansion; diagnostic infrastructure	$5-10B (long-term if access improves)

Patent and Exclusivity Summary

Product	Indication	US Exclusivity	Key Risk
Mounjaro / Zepbound (tirzepatide)	Diabetes, obesity, OSA	NCE expires 2027; formulation patents to Dec 2037	Biosimilar challenges to formulation patents; Paragraph IV filings
Jardiance (empagliflozin)	Diabetes, HF, CKD	Compound patent May 2028	Generic entry 2028-2029
Trulicity (dulaglutide)	Diabetes	2027	Biosimilar competition imminent
Verzenio (abemaciclib)	Breast cancer	Not disclosed	Patent challenges; biosimilar development
Taltz (ixekizumab)	Psoriasis, PsA, AxSpA	Not disclosed	Biosimilar competition (timeline uncertain)
Kisunla (donanemab)	Alzheimer's	Recently approved 2024 (exclusivity ~2036-2039 est.)	Patent challenges; competitive biosimilars

Patent Cliff Summary: Eli Lilly faces a significant patent cliff in the 2027-2028 timeframe with potential loss of exclusivity for tirzepatide (NCE expires 2027, though formulation patents to 2037), Trulicity (2027), and Jardiance (2028). Combined, these products generated approximately $42-45 billion in revenue in 2025. The company's strategy to mitigate this cliff includes oral orforglipron, retatrutide as next-generation incretins, and portfolio diversification.

Ada Patient Finder Analysis - Priority Matrix

Tier 1: Highest Priority Opportunities

Product	Indication	Fit Score	Addressable Population	Net Revenue/Patient/Year	Key Rationale
Zepbound	OSA + Obesity	**9/10**	25-35 million	$6,360	**70-80% OSA undiagnosed;** exceptional Ada symptom detection (snoring + daytime sleepiness); first and only FDA-approved OSA therapy
Mounjaro	Type 2 Diabetes	**8/10**	10-15 million eligible	$6,138	**22-28% T2DM undiagnosed** with 4-7 year average diagnostic delay; classic symptoms (polyuria, polydipsia); huge market

Tier 2: High Priority Opportunities

Product	Indication	Fit Score	Addressable Population	Net Revenue/Patient/Year
Taltz	PsA + AS	**7/10**	0.8-1.3 million	$39,600
Omvoh	IBD (UC + Crohn's)	**7/10**	0.4-0.6 million	$39,600

Commercial Opportunity Summary

Conservative 3-Year Scenario:

- **Patients found via Ada:** 200,000-300,000 across Zepbound, Mounjaro, Taltz, Omvoh

- **Incremental first-year drug revenue:** $1.5-2.5 billion
- **Ada Patient Finder fees (8-12% of first-year revenue):** $120-300 million

Product	Patients Found	Net Revenue/Patient	Total First-Year Revenue	Ada Fee (8-12%)
Zepbound (OSA)	100,000	$6,360	$636 million	$50.9-76.3 million
Mounjaro (T2DM)	50,000	$6,138	$306.9 million	$24.6-36.8 million

Risks and Challenges

Eli Lilly faces a complex risk landscape spanning competitive, regulatory, financial, and operational domains. Key material risks include:

Risk Category	Key Concerns	Impact Level
Patent Expirations	Mounjaro/Zepbound NCE expires 2027; Trulicity 2027; Jardiance 2028 - $40B+ revenue at risk	**HIGH**
Competitive Pressure	Novo Nordisk oral GLP-1s, biosimilars, compounded alternatives; pricing erosion (5% in Q4 2025)	**HIGH**
IRA Pricing Pressure	Medicare negotiations (2026+ for select drugs); potential 25-60% price cuts	**HIGH**
Regulatory Risk	Orforglipron approval uncertainty (April 2026); ARIA safety (Kisunla); manufacturing quality	**MEDIUM-HIGH**
Manufacturing Constraints	Supply constraints despite $50B+ investment; new facility startup execution risk	**MEDIUM**
Pipeline Execution	Retatrutide Phase III efficacy risk; 75% of pipeline outside incretins must succeed	**MEDIUM**
Concentration Risk	56% of 2025 revenue from tirzepatide franchise creates single-product dependence	**HIGH**

Outlook and Valuation Context

Medium-Term Revenue Targets

Year	Revenue Target	Growth vs Prior Year	Key Drivers
2026 Guidance	$80-83 billion	+25%	Sustained tirzepatide growth; orforglipron launch (if approved)
2027 Analyst Projections	$87-94 billion	+8-13%	Orforglipron ramp; retatrutide potential approval
2030 Analyst Projections	$113 billion	~20% CAGR (2024-2030)	Mounjaro $36B, Zepbound $25.5B, orforglipron $30-40B, diversified portfolio

Peer Comparison (Projected 2030 Revenue)

Rank	Company	Projected 2030 Revenue	2024-2030 CAGR
1	**Eli Lilly**	**$113 billion**	**~20%**
2	Novo Nordisk	$84 billion	~12-15%
3	Roche	~$75-80 billion (est.)	~3-5%
4	Merck	~$70-75 billion (est.)	~5-7%

Market Capitalization (March 2026): Eli Lilly is already the **most valuable pharmaceutical company** at $897-953 billion, ranking among the top 13-14 most valuable companies globally across all sectors. This represents over 10x growth from ~$84 billion when David Ricks became CEO in January 2017.

References

1. Salestools.io. "Eli Lilly Headquarters." https://salestools.io/en/report/eli-lilly-headquarters
2. Downtown Indy. "Eli Lilly and Company." https://downtownindy.org/go/eli-lilly-and-company
3. PR Newswire. "Lilly Reports Full Q4 2024 Financial Results and Provides 2025 Guidance." February 6, 2025. Link
4. Pharmaceutical Technology. "Eli Lilly Soars Past Expectations to Hit 45% Sales Growth in 2025."
5. Companies Market Cap. "Eli Lilly Market Cap." https://companiesmarketcap.com/eli-lilly/marketcap/
6. BiopharmaDive. "Lilly Earnings, Guidance Q4 2025."
7. PR Newswire. "Lilly Reports Third Quarter 2025 Financial Results."
8. Fintool. "Eli Lilly Q4 Earnings Beat." Link
9. Global PharmCube. "Eli Lilly Verzenio Sales 2025."
10. Drug and Device World. "Lilly 2024 Revenue Stock Increase." February 6, 2025.

Note: Full reference list with 86 numbered citations available in complete markdown report. Major sources include: Eli Lilly investor relations materials, SEC filings, FDA approvals, peer-reviewed medical literature, pharmaceutical industry publications (BiopharmaDive, Fierce Pharma, Pharmaceutical Technology), financial data providers (Companies Market Cap, Stock Analysis), and disease prevalence databases (CDC, SEER, Alzheimer's Association, National Psoriasis Foundation).

Eli Lilly Deep Dive - Ada Cockpit - March 2026

Report Classification: Investor-Grade Research - Confidential

126,517 bytes | 86 sources | 13 mandatory sections completed